市场调查报告书
商品编码
1422960
2024-2032 年经导管肺动脉瓣市场(按技术、原料、应用、最终用户和地区划分)Transcatheter Pulmonary Valve Market by Technology, Raw Material, Application, End User, and Region 2024-2032 |
2023年,全球经导管肺动脉瓣市场规模达到8,830万美元。展望未来, IMARC Group预计到2032年市场规模将达到1.811亿美元,2024-2032年复合年增长率(CAGR)为8.06%。各种心血管疾病(CVD)发生率的增加、广泛的研发(R&D)活动以及老年人口的增加是推动市场发展的一些关键因素。
经导管肺动脉瓣是指由牛、猪或人类心臟组织製成的人工瓣膜。它被广泛用于替换渗漏或狭窄的肺动脉瓣以改善血流,与开放性手术相比切口更少,恢復更快。这些瓣膜透过细而柔性的管子(导管)插入大血管,涉及微创 (MI) 手术。经导管肺动脉瓣置换术疼痛较少,恢復期较短,有助于改善症状,同时降低医疗併发症的风险。它还有助于恢復血流并减少主动脉瓣狭窄的体征和症状,例如胸痛、气短、昏厥和疲劳。因此,这些瓣膜在心臟异常、肺动脉瓣逆流、闭锁、狭窄和动脉干等方面有广泛的应用。
全球风湿性心臟病、高血压心臟病、脑血管疾病和发炎性心臟病等各种心血管疾病(CVD)发生率的上升是推动市场成长的关键因素之一。与此一致的是,老年人口的增加以及与严重主动脉瓣狭窄和二尖瓣和三尖瓣逆流相关的退化性异常盛行率的增加有利于市场的成长。此外,产品在儿科经导管肺治疗中的广泛采用也促进了市场的成长。这主要归因于肺动脉狭窄、闭锁、法洛氏四合症和其他相关疾病的发生频率不断增加,这促进了产品作为有效治疗选择的采用。除此之外,人工智慧(AI)在经导管肺动脉瓣置换术(TPVR)手术中的整合,因为它有助于术前规划、识别风险因素以及加强诊断和临床决策,从而推动了市场成长。此外,对球囊扩张技术的需求不断增长,因为它涉及更快、更简单的过程,并提供高精度的结果,这对市场成长产生了积极影响。除此之外,Hydra 主动脉瓣的推出正在推动市场成长,Hydra 主动脉瓣是一种由镍钛合金製成的自扩张超环形主动脉系统,可精确放置瓣膜并确保原位部署。其他因素包括对创新心臟瓣膜的需求不断增长、高血压病例数量不断增加、医疗保健行业不断增长、消费者支出能力不断增强、广泛的研发(R&D) 活动以及政府实施各种旨在开发高效心臟瓣膜的倡议经导管肺动脉瓣预计将为市场创造积极的前景。
The global transcatheter pulmonary valve market size reached US$ 88.3 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 181.1 Million by 2032, exhibiting a growth rate (CAGR) of 8.06% during 2024-2032. The increasing incidence of various cardiovascular diseases (CVDs), extensive research and development (R&D) activities, and the rising geriatric population represent some of the key factors driving the market.
A transcatheter pulmonary valve refers to an artificial valve made from cow, pig, or human heart tissue. It is widely used to replace leaky or narrowed pulmonary valves to improve blood flow, with fewer incisions and faster recovery than open surgery. These valves are inserted through a thin, flexible tube (catheter) into a large blood vessel involving a minimally invasive (MI) procedure. Transcatheter pulmonary valve replacement involves less pain and a shorter recovery period and helps in improving symptoms while lowering the risk of medical complications. It also helps to restore blood flow and reduce the signs and symptoms of aortic valve stenosis, such as chest pain, shortness of breath, fainting, and fatigue. As a result, these valves find extensive applications in cardiac anomaly, pulmonary regurgitation, atresia, stenosis, and truncus arteriosus.
The rising incidences of various cardiovascular diseases (CVDs), such as rheumatic heart disorders, hypertensive heart diseases, cerebrovascular diseases, and inflammatory heart diseases across the globe, are among the key factors driving the market growth. In line with this, the rising geriatric population and increasing prevalence of degenerative abnormalities associated with severe aortic stenosis and mitral and tricuspid regurgitation are favoring the market growth. Moreover, the widespread product adoption in the treatment of pediatric transcatheter pulmonary is contributing to the market growth. This can be primarily attributed to the increasing frequency of pulmonary stenosis, atresia, tetralogy of Fallot, and other related disorders, which is facilitating the product adoption as an effective treatment option. Apart from this, the integration of artificial intelligence (AI) in the transcatheter pulmonary valve replacement (TPVR) procedure, as it assists in pre-procedural planning, identifying risk factors, and enhancing diagnosis and clinical decision-making, is providing an impetus to the market growth. Additionally, the increasing demand for balloon-expanded technology as it involves a faster and simpler process and offers high accuracy and precision of the result is positively influencing the market growth. Besides this, the launch of the hydra aortic valve, which is a self-expanding supra-annular aortic system made of nitinol that allows precise placement of the valve and ensures orthotopic deployment, is propelling the market growth. Other factors, including growing demand for innovative heart valves, an increasing number of hypertension cases, escalating growth in the healthcare industry, rising expenditure capacities of consumers, extensive research and development (R&D) activities, and the implementation of various government initiatives to develop efficient transcatheter pulmonary valves, are anticipated to create a positive outlook for the market.
IMARC Group provides an analysis of the key trends in each segment of the global transcatheter pulmonary valve market, along with forecasts at the global, regional, and country level from 2024-2032. Our report has categorized the market based on technology, raw material, application, and end user.
Balloon-Expanded Transcatheter Valve
Self-Expanded Transcatheter Valve
The report has provided a detailed breakup and analysis of the transcatheter pulmonary valve market based on the technology. This includes balloon-expanded transcatheter valve and self-expanded transcatheter valve. According to the report, balloon-expanded transcatheter valve represented the largest segment.
Tissue Engineered
Synthetic
The report has provided a detailed breakup and analysis of the transcatheter pulmonary valve market based on the raw material. This includes tissue engineered and synthetic. According to the report, tissue engineered represented the largest segment.
Tetralogy of Fallot
Cardiac Anomaly
Pulmonary Atresia
Pulmonary Stenosis
Pulmonary Regurgitation
Truncus Arteriosus
Others
The report has provided a detailed breakup and analysis of the transcatheter pulmonary valve market based on the application. This includes tetralogy of fallot, cardiac anomaly, pulmonary atresia, pulmonary stenosis, pulmonary regurgitation, truncus arteriosus, and others. According to the report, tetralogy of fallot represented the largest segment.
Adult
Pediatric
The report has provided a detailed breakup and analysis of the transcatheter pulmonary valve market based on the end user. This includes adult and pediatric. According to the report, adult represented the largest segment.
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others);Latin America (Brazil, Mexico, and others); and Middle East and Africa. According to the report, North America was the largest market for transcatheter pulmonary valve. Some of the factors driving the North America transcatheter pulmonary valve market included the rising geriatric population, growing demand for innovative heart valves, and various technological advancements.
The report has also provided a comprehensive analysis of the competitive landscape in the global transcatheter pulmonary valve market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Abbott Laboratories, Artivion Inc., Boston Scientific Corporation, Braile Biomedica, Colibri Heart Valve LLC, Edwards Lifesciences Corporation, JenaValve Technology Inc., Labcor Laboratorios Ltda., Medtronic plc, Venus Medtech (Hangzhou) Inc., etc.